Compare HUCK & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUCK | CDXS |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | 876 | N/A |
| Industry | Computer Software: Prepackaged Software | Major Chemicals |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.3M | 154.4M |
| IPO Year | 2018 | 2008 |
| Metric | HUCK | CDXS |
|---|---|---|
| Price | $2.75 | $1.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.17 | ★ $6.14 |
| AVG Volume (30 Days) | 681.7K | ★ 846.3K |
| Earning Date | 12-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.92 | ★ 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | $138,590,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | $1.33 | $18.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.57 | ★ 32.30 |
| 52 Week Low | $2.96 | $0.96 |
| 52 Week High | $3.55 | $2.98 |
| Indicator | HUCK | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 27.09 | 36.20 |
| Support Level | N/A | $0.96 |
| Resistance Level | $3.22 | $1.24 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 8.00 | 23.53 |
Huckleberry.ai Inc, formerly Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.